SecBot SecBot
SECBOTREPLAY Home › Report › BIIB

BIIB · DZP Phase 3 post-hoc data at ACR

Biogen Inc. · PRESS-RELEASE filed Nov 9, 2026 at 01:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 9, 2026 at 01:00 ET

Biogen and UCB presented post-hoc analyses of the Phase 3 PHOENYCS GO trial of dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) at ACR Convergence 2026. The data showed DZP plus standard of care was associated with higher response rates on the novel TRM-SLE measure and greater rates of sustained low disease activity and remission versus placebo. DZP remains investigational and not approved by any health authority.

  • Post-hoc analysis of Phase 3 PHOENYCS GO using TRM-SLE showed DZP plus SOC vs placebo plus SOC achieved TRM-SLE-50 (61.2% vs 43.2%) and TRM-SLE-100 (52.5% vs 36.8%) through Week 48.
  • Sustained LLDAS at Weeks 40/44/48: DZP 24.0% vs placebo 10.3% (nominal p=0.0012); sustained DORIS: 11.5% vs 4.7% (nominal p=0.0253).
  • Primary endpoint BICLA response at Week 48 was met (50% vs 35%; p=0.011) as previously reported in The Lancet.
  • DZP is an investigational biologic not approved by any health authority worldwide.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access